SCHEMBL890542

SCHEMBL890542

CCc1[nH]c2ccc(F)cc2c(=O)c1-c1cc(F)cc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 3/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.45
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
MPO P05164 3/20 0.44
PIK3CD O00329 1/20 0.42
GHSR Q92847 1/20 0.42
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
FEN1 P39748 1/20 0.39
HSD17B10 Q99714 1/20 0.38
KIF11 P52732 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10063269 0.81 KDM4E (0.51) KDM4EALDH1A1GLAGAAHTT
SCHEMBL890553 0.79 KDM4E (0.50) KDM4EALDH1A1GLAGAAHTT
SCHEMBL2730902 0.79 KDM4E (0.50) KDM4EALDH1A1GLAGAAHTT
SCHEMBL2729534 0.78 ALDH1A1 (0.49) KDM4EALDH1A1GLAGAAHTT
SCHEMBL10120345 0.75 PIK3CD (0.55) KDM4EALDH1A1GLAGAAHTT
SCHEMBL15886438 0.75 KIF11 (0.46) KDM4EALDH1A1GLAGAAHTT
SCHEMBL12209113 0.73 KIF11 (0.49) KDM4EALDH1A1GLAGAAHTT
SCHEMBL24486654 0.72 KIF11 (0.44) KDM4EALDH1A1GLAGAAHTT
SCHEMBL6216591 0.72 KEAP1 (0.44) KDM4EALDH1A1GLAGAAHTT
SCHEMBL14668858 0.69 KDM4E (0.76) KDM4EALDH1A1GLAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
EP-2445898-A2 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS Amgen, Inc (US) 2012-05-02 EP disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 KDM4E 1436/4885ALDH1A1 3735/4885GLA 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.